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ABSTRACT 
Autosomal recessive mutations in the 17a-hydroxysteroid dehy- 
drogenase 3 gene impair the formation of testosterone in the fetal 
testis and give rise to genetic males with female external genitalia. 
Such individuals are usually raised as females, but virilize at the time 
of expected puberty as the result of increases in serum testosterone. 
Here we describe mutations in 12 additional subjects/families with 
this disorder. The 14 mutations characterized to date include 10 
missense mutations, 3 splice junction abnormalities, and 1 small 
deletion that results in a frame shift. Three of these mutations have 
occurred in more than 1 family. Complementary DNAs incorporating 
9 of the 10 missense mutations have been constructed and expressed 
in reporter cells; 8 of the 9 missense mutations cause almost complete 
loss of enzymatic activity. In 2 subjects with loss of function, missense 
mutations testosterone levels in testicular venous blood were very 
low. Considered together, these findings strongly suggest that the 
common mechanism for testosterone formation in postpubertal sub- 
jects with this disorder is the conversion of circulating androstenedi- 
one to testosterone by one or more of the unaffected 17P-hydroxys- 
teroid dehydrogenase isoenzymes. (J Clin Endocrinol Metab 81: 
130-136, 1996) 
T HE ESTABLISHMENT of the male phenotype during embryogenesis is dependent on two hormones se- 
creted by the fetal testes. The peptide hormone Mullerian 
inhibiting hormone is responsible for regression of the Mul- 
lerian ducts, and the steroid hormone testosterone mediates 
development of the male urogenital tract and external gen- 
italia (reviewed in Ref. 1). Disorders that disrupt the syn- 
thesis or action of testosterone impair male phenotypic de- 
velopment and cause the condition of human intersex termed 
male pseudohermaphroditism. Defects in androgen action 
are the most common of these disorders and include muta- 
tions in the androgen receptor gene and mutations in the 
steroid 5a-reductase 2 gene, which encodes an enzyme re- 
sponsible for the conversion of testosterone to dihydrotes- 
tosterone in the urogenital tract (2). Autosomal recessive 
mutations have also been described that impair each of the 
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five enzymatic reactions involved in the conversion of cho- 
lesterol to testosterone, including the side-chain cleavage 
reaction, 3/3-hydroxysteroid dehydrogenase (3/3HSD), 17a- 
hydroxylase/l7,20-lyase, and 17PHSD (3). We identified the 
defect in the latter disorder as the consequence of mutations 
in the 17PHSD-3 gene and described six different mutations 
in five unrelated affected individuals (three homozygotes 
and two compound heterozygotes) (4). 
17PHSD deficiency was originally described by Saez and 
his colleagues (5,6); the characteristic phenotype is that of a 
46,XY individual with testes and male Wolffian duct-derived 
urogenital structures (epididymides, vas deferentia, seminal 
vesicles, and ejaculatory ducts) but female external genitalia 
(7-9). Such individuals are usually classified as female at 
birth and raised as females, but at the time of expected 
puberty, plasma testosterone rises to levels that in some 
instances approximate the normal male range. As a conse- 
quence, many such individuals undergo a marked viriliza- 
tion during the teenage years. Two explanations have been 
proposed to explain the fact that the impairment of testos- 
terone synthesis is more severe during embryogenesis than 
in later life, namely that testosterone can be formed in ex- 
traglandular tissues from the circulating precursor andro- 
stenedione that accumulates in the disorder (10) and that the 
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impairment of the enzyme is incomplete, so the testis can 
secrete some testosterone (11). 
In the present study, we characterized the mutations in 12 
additional individuals/families with 17PHSD-3 deficiency 
and studied the functional consequences of some of the mu- 
tant enzymes expressed in reporter cells. Most of these mu- 
tations cause either single amino acid substitutions or disrupt 
splice acceptor sites, and all but 1 of the missense mutations 
characterized to date impair enzyme function completely. 
This latter finding is in agreement with studies in 2 of the 
subjects, in whom we show that negligible amounts of tes- 
tosterone are secreted by the testes. We conclude that circu- 
lating testosterone in most individuals with this disorder is 
derived from extraglandular conversion of androstenedione 
to testosterone by 1 or more of the unaffected 17PHSD 
isoenzymes. 
Subjects and Methods 
Subjects 
Four of the subjects/families shown in Table 1 were previously re- 
ported in detail, namely 17HSD-3-Gaza (11-141, 17HSD-3-Sao Paulo 3 
(15), 17HSD-3-Syria (lo), and 17HSD-3-New York (16). Two others 
(17HSD-3-Dallas and 17HSD-3-Sao Paulo 1) have been described in 
capsule form (4). The remaining 11 subjects/families have not previ- 
ously been reported. 
17HSD-3-&m Francisco 1. This girl was evaluated at University of 
California-San Francisco at age 15 yr. The external genitalia had been 
considered normal at birth, but at 7 months of age she was noted to have 
a mass in the right labia majora. Beginning at age 13 yr, she noted breast 
enlargement, deepening of the voice, and enlargement of the clitoris. The 
family history was uninformative, and two siblings were normal. On 
physical examination she had facial hirsutism, 6 X 6-cm breast tissue, a 
3 X 1.5-cm clitoris, scrotalization of the labia majora, and a blind-ending 
vagina. The karyotype was 46,XY. Endocrine findings are summarized 
in Table 2. Gonadectomy was performed; the testes measured 3 X 2 cm, 
and by microscopic examination the seminiferous tubules contained 
mostly Sertoli cells and a few germ cells. DNA was prepared from tissue 
blocks. 
27HSD-3-5~1 Francisco 2. This girl was thought to be normal at birth, but 
was evaluated at age 13 yr at University of California-San Francisco 
because of a deepening voice, hirsutism, male musculature, and an 
enlarged clitoris. The family history was uninformative, and a 15-yr-old 
sister was normal. Breasts were Tanner stage III, and pubic hair was 
Tanner stage IV. The vagina was blind-ending, and masses (3.5 X 2.5 cm) 
were palpable in the labia majora. The karyotype was 46,XY. Plasma 
androgen levels are summarized in Table 2. After extensive psychiatric 
and social evaluation, she underwent bilateral gonadectomy and partial 
resection of the clitoris; spermatic venous blood was obtained at the time 
of surgery, and the levels of testosterone and androstenedione were 
compared with those previously reported in normal men (17,18) (Table 
2). The epididymides were hypoplastic. The seminiferous tubules con- 
tained Sertoli cells but no germ cells. DNA was prepared from tissue 
blocks. 
27HSD-3-Munich. This female infant was thought to be normal until age 
3 weeks, when she was found to have masses in the labia majora bi- 
laterally; these masses were shown by biopsy to be testes. The karyotype 
was 46,XY. A hCG stimulation test was performed at 6 months of age; 
plasma testosterone rose from less than 20 to 26 ng/dL, and plasma 
androstendione rose from 50 to 161 ng/dL. Bilateral gonadectomy was 
performed at age 8 months. DNA was prepared from peripheral blood. 
17HSD-3-Stony Brook. This newborn infant with ambiguous genitalia 
was the product of a 35-week twin gestation; the other twin is 46,Xx and 
has a normal female phenotype. The parents are first cousins of German 
descent; a 12-yr-old half-brother is normal. On physical examination the 
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TABLE 2. Endocrine findings in four subjects with 17PHSD-3 deficiency 
Peripheral vein Spermatic vein Estimated testicular 
Subject Testosterone Androstenedione Testosterone Androstenedione TIA testosterone secretion 
(ng/dL) (ng/dL) (ng/dL) (ng/dL) (mgiday)” 
17HSD-San Francisco 1 209 883 3,678 R 43,450 0.09 0.2 
5,198 L 55,870 0.09 
17HSD-San Francisco 3 (subject 2) 148 344 993 R >44,440 .02 0.05 
1,206 L >44,440 .03 
Normal adult male values 491-1089 85-242 
Kelch et al. (18) 71,200 -t 7,900 2,230 i 1,360 32 4.1 
Weinstein et al. (17) 75,100 i 11,400 3,070 t 790 24 4.3 
n Testosterone secretion (rig/d) = testicular volume (g) X 0.1 mL plasma flow/g. min X 1442 min/day X [Ttesbeular V(,ln plZrhmZ, - 
T peripheral Yeln plasmalw/mL. 
Plasma flow approximates 0.1 mL/g . min in a variety of species, including man (29). For the two 17HSD subjects, testicular volume was 
estimated by a testiculometer, and for the normal adult males, an average testicular volume of 20 mL was assumed. 
infant had clitoromegaly (1.5 cm) and posterior fusion and scrotalization 
of the labia majora, which contained palpable masses bilaterally. The 
karyotype was 46,XY. At 9 h of life, serum testosterone was 86 ng/dL, 
dihydrotestosterone was 12 ng/dL, and androstenedione was 215 ng/ 
dL. DNA was prepared from peripheral blood. 
37HSD-3-Son Antonio. This 16-yr-old Iranian girl was evaluated at 
Wilfred Hall U.S. Air Force Hospital because of hirsutism, clitoromegaly, 
and failure to menstruate. The karyotype was 46,XY. A diagnosis of 
17PHSD-3 deficiency was made on the basis of a male level of testos- 
terone and an elevated level of androstenedione (exact values not avail- 
able). DNA was prepared from cultured skin fibroblasts. 
17HSD-3-Bethesdn. This girl was thought to be normal until age 10 yr, 
when a testis was discovered in a right herniorrhaphy sac. Breast en- 
largement was noted by age 13 yr, but because of failure to menstruate 
she was evaluated at age 15 yr in Portland, ME, where a diagnosis of 
17PHSD-3 deficiency was made. This diagnosis was confirmed at the 
NIH, where she was found to have a serum testosterone level of 221 
ng/dL and a serum androstenedione level of 1031 ng/dL. The parents 
are from Poland; a sister and two brothers are normal, and two sisters 
are dead. In May 1980, a bilateral gonadectomy and clitoroplasty were 
performed. She was subsequently treated with estrogen and 
medroxyprogesterone (with successful feminization) and underwent a 
vaginoplasty to enlarge a 5-cm blind-ending vagina. DNA was prepared 
from tissue blocks. 
17HSD-3-Sno Pa& 2. This woman was evaluated at age 21 yr because 
of absent breast development and failure to menstruate. Facial hirsutism 
and clitoromegaly were noted by age 13 yr. The parents are first cousins, 
and she has two brothers with ambiguous genitalia. On physical ex- 
amination, she had temporal hair regression and hirsutism of the lips, 
chin, areolae, and abdomen. The clitoris measured 9 X 2 cm, and a 6-cm 
blind-ending vagina was present. Gonads were palpable in the inguinal 
canals. No breast tissue was palpable. The karyotype was 46,XY. Serum 
testosterone was 330 ng/dL, and androstenedione was 1010 ng/dL. 
Serum LH was 27 U/L, and serum FSH was 29 U/L. After psychological 
and psychiatric examination, bilateral orchidectomy and clitoral resec- 
tion were performed. Histological examination of the testes revealed 
abundant Leydig cells and seminiferous tubules that contained Sertoli 
cells but no germ cells. She is currently receiving estrogen replacement 
therapy. DNA was prepared from peripheral blood. 
17HSD-3-Sao Pulllo 4. This subject was born with ambiguous genitalia 
and was registered and raised as a female until age 10 yr, at which time 
he began to function as a male. By age 16 yr, increased body hair, male 
pattern muscle development, and penile growth were prominent. At age 
21 yr, psychological testing confirmed that he had a male gender iden- 
tity. He is the offspring of a first cousin marriage and is one of seven 
siblings, including a similarly affected younger brother. Physical exam- 
ination revealed a male habitus, no palpable breast tissue, and male 
pattern facial and chest hair. The penis measured 6.8 X 2.5 cm with 
perineoscrotal hypospadias; the scrotum was bifid, and a blind-ending 
vagina was present. Testes (5 X 3 cm) were palpable in the inguinal 
canals. Endocrine findings included serum testosterone of 285 ng/dL 
and serum androstenedione of 480 ng/dL; these values increased to 525 
and 1800 ng/dL, respectively after hCG administration and did not 
change significantly after 4 days of dexamethasone administration. Se- 
rum LH was 38 U/L, and serum FSH was 64 U/L. He subsequently 
underwent surgical repair of the hypospadias. 
27HSD-3-Dnllus. This 17.yr-old girl with known hemoglobinopathy (SC 
disease) was evaluated because of clitoromegaly (4 cm) and failure to 
menstruate. The family history was uninformative. On physical exam- 
ination a blind-ending vagina was present, testes were palpable in the 
inguinal canals bilaterally, no breast tissue was palpable, and there was 
no hirsutism. No uterus was identified by ultrasonography. The karyo- 
type was 46,XY. Serum testosterone was 740 ng/dL, serum andro- 
stenedione was 880 ng/dL, and serum dihydrotestosterone averaged 35 
ng/dL. Serum LH was 27 U/L, and FSH was 51 U/L. The decision was 
made to remove the testes. At surgery, the testes measured 3 X 1.8 cm 
with separate epididymis, and vasography revealed vasa deferentia, 
seminal vesicles, and ejaculatory ducts that terminated in the position 
of Gartner’s ducts adjacent to the vaginal orifice. On histological exam- 
ination, Leydig cells were abundant, and the seminiferous tubules con- 
tained Sertoli cells and occasional spermatocytes, but no spermatids or 
spermatozoa. Shortly after surgery she died in an accident. DNA was 
prepared from cultured skin fibroblasts. 
17HSD-3-San Francisco 3. These two sisters were the products of a non- 
consanguineous marriage. Subject 1 was seen at age 13 yr because of 
failure of breast development and deepening of the voice. No breast 
tissue was palpable. The clitoris measured 4.5 x 1 cm, and 3 X 1.4-cm 
masses were present in the inguinal areas. The vagina was blind-ending 
and shallow. The karyotype was 46,XY. Endocrine values are given in 
Table 2. Bilateral orchidectomy was performed; the seminiferous tubules 
contained Sertoli cells and rare germ cells. She was treated with con- 
jugated estrogens and medroxyprogesterone. DNA was prepared from 
cultured skin fibroblasts. Subject 2 was evaluated at age 12 yr; an en- 
larged clitoris in an otherwise normal female infant had been noted at 
birth, but she was not evaluated until the sister was diagnosed. No breast 
tissue was palpable. The clitoris measured 4 X 1 cm, and the blind- 
ending vagina was 2.5 cm in depth. Testis-like masses (4 X 2 cm) were 
palpable in the inguinal regions. The karyotype was 46,XY. The endo- 
crine findings are shown in Table 2. Bilateral orchidectomy and a clitoral 
resection were performed, and the testicular veins were cannulated for 
measurement of androstenedione and testosterone levels at the time of 
surgery (Table 2). The seminiferous tubules contained Sertoli cells and 
occasional spermatocytes, and the epididymis was histologically nor- 
mal. She was treated with premarin/medroxyprogesterone, and at age 
16 yr she underwent vaginal dilatation via the Frank procedure. DNA 
was prepared from tissue blocks. 
17HSD-3-Sno Pu~llo 1. This 15-yr-girl was evaluated because of the ab- 
sence of breast development and failure to menstruate. The family 
history was uninformative, and four siblings were normal. On physical 
examination she had a deep voice; coarse hair over the lip, chin, and 
abdomen; clitoromegaly (8 X 2 cm); a blind-ending vagina (6 cm in 
depth); and no palpable breast tissue. A 4 X 2.5.cm mass was palpable 
in the left inguinal canal. Serum testosterone was 620 ng/dL, and serum 
androstenedione was 980 ng/dL; these values increased to 810 and 1810 
17PHSD-3 DEFICIENCY 133 
ng/dL after hCG administration and changed very little after dexa- 
methasone administration. LH was 29 U/L, and FSH was 30 U/L. After 
careful psychological testing she underwent bilateral orchidectomy (the 
right testis was intraabdominal) and clitoral resection. Histological ex- 
amination of the testes revealed abundant Leydig cells and seminiferous 
tubules that contained predominately Sertoli cells. She now receives 
estrogen replacement. DNA was prepared from peripheral blood. 
17HSDJ-Pittsburgh, This 13-yr-old girl was referred to the Children’s 
Hospital of Pittsburgh because of clitoromegaly and coarsening of the 
voice. The family history was incomplete, but she has four normal 
brothers. Physical examination revealed no palpable breast tissue, cli- 
toromegaly (4 x 3 cm), scrotalization of the labia majora, and bilateral 
masses in the inguinal regions. Karyotype was 46,XY. Serum andro- 
stenedione was 512 ng/dL, and serum testosterone was 212 ng/dL. 
After hCG stimulation, the androstenedione level was 817 ng/dL, and 
testosterone was 344 ng/dL. After LH-releasing hormone administra- 
tion, the androstenedione level was 675 ng/dL, and testosterone was 377 
ng/dL. After careful evaluation, the decision was made to remove the 
gonads and administer estrogen. The right undescended testis exhibited 
Leydig cell hyperplasia and seminiferous tubules lined with Sertoli cells, 
but no germ cells, and the left partially descended testis had tubules with 
germ cell hyperplasia and a maturation arrest. DNA was prepared from 
peripheral blood. 
17HSD-3-Indianapolis. This infant was noted at birth to have perineo- 
scrotal hypospadias with a single orifice on the perineum and a bifid 
scrotum with rugated labioscrotal folds. The karvotvue was 46,XY. After 
a hCG stimulati& test at 4 months of age, the plasma testosterone level 
was 430 ng/dL, and the plasma dihydrotestosterone level was 12 ng/dL. 
Steroid 5a-reductase activity in cultured genital skin fibroblasts was low 
(0.6 pmol/h.mg protein; normal range, l-100), and the androgen re- 
ceptor level was normal (20 fmol/mg protein; normal, >151. A tentative 
diagnosis of steroid 5cY-reductase 2 deficiency was made, but the coding 
sequence for this gene was normal. It was decided to raise this child as 
a female, and she was gonadectomized. She was subsequently treated 
with conjugated estrogen and underwent vaginal dilatation at age 13 yr. 
Genomic DNA isolation 
Genomic DNA was extracted from cultured fibroblasts and white 
blood cells as described previously (19) using an Applied Biosystems 
model 340A Nucleic Acids Extractor. In some cases genomic DNA was 
extracted from embedded and formalin-fixed tissue specimens. Briefly, 
small sections of the tissue block were deparafinized with xylene and 
then rehydrated by rinsing in a graded series of ethanol solutions. The 
tissue was treated twice with proteinase K 1250 pg/mL in 10 mmol/L 
Tris-chloride (pH 8.0) and 1 mmol/L ethylenediamine tetraacetate-1% 
(wt/vol) SDS; 55 C; l-16 h), and DNA was isolated using a kit (IsoQuick 
Nucleic Acid Extractor Kit, Microprobe Corp., Garden Grove, CA). The 
purified DNA was then used as a template in PCR, as described below. 
Mutation detection 
Mutations in the 17HSD 3 gene were detected by amplification of 
individual exons using the PCR and single strand DNA conformation 
uolvmoruhism analvsis, as ureviouslv described (4). The DNA se- 
quences hf the oligonucleotide pairs used to amplify the 11 exons of the 
gene are shown in Table 3. Exons 1, 3, 4,5, 7, 9, and 11 were amplified 
with a thermocycler program consisting of 30 cycles of 94 C for 30 s, 65 
C for 15 s, and 72 C for 30 s. Exons 2,6,8, and 10 were amplified using 
a thermocycler program consisting of 30 cycles of 94 C for 30 s, 62 C for 
15 s, and 72 C for 30 s. The nucleotide sequence of exons suspected of 
harboring mutations on the basis of single strand DNA conformation 
polymorphism analysis were determined by cycle sequencing using a 
thermostable DNA polymerase (20). 
Expression analysis in transfected 293 cells 
Site-directed mutagenesis reactions in which individual missense 
mutations were introduced into an expressible complementary DNA 
(cDNA) vector were performed with a Mutagene Kit (Bio-Rad Labora- 
tories, Richmond, CA). The mutagenic oligonucleotide primers were 21 
bases in length. Manipulated DNA fragments were subjected to DNA 
sequence analysis and then transfected into cultured human embryonic 
kidnev 293 cells (CRL 1573, American Tvue Culture Collection, Rock- 
ville, MD) using a calcium phosphate precipitation protocol (21). Forty- 
eight hours after transfection, cells were analyzed for 17PHSD activity 
as previously described (4, 22). 
Immunoblotting of transfected cell extracts was carried out using an 
antipeptide antibody directed against residues 303-310 of the 17PHSD-3 
isoenzyme. A polyclonal antibody was raised in rabbits by standard 
methods (23) after coupling the synthetic peptide to bovine thyroglob- 
ulin. Peptide-specific antibodies were purified by chromatography on 
antigen-agarose beads and used directly in the immunoblotting reac- 
tions. Aliquots of transfected cell extracts (5 kg protein) were separated 
by electrophoresis through 12% (wt/voll polyacrylamide gels contain- 
ing 0.1% (wt/vol) SDS. Separated proteins were transferred to nitro- 
cellulose filters (Novex Corp., San Diego, CA) by electroblotting and 
subjected to a standard immunoblotting protocol (23). Enhanced chemi- 
TABLE 3. Sequence and locations of oligonucleotides in 17PHSD3 gene used for PCRs 
Oligonucleotide Location Amplification target Sequence 5’ ---f 3’ 
1 5’-Untranslated, Exon 1 Exon 1 ACGGCCAGGGCTGAAACAGTCTGTT 
2 Intron 1 AGTAACAAGCAGGAACAACAGCAG 
3 Intron 1 Exon 2 TGAATTACTGTCTTTTAAAAGCA 
4 Intron 2 AATACAAGGGAGGAGAAAGTCCCCA 
5 Intron 2 Exon 3 GCTCATCATCCTTGTCTCTTGGTTT 
6 Intron 3 GAGGGCTCCACACACATCTCCCTTA 
7 Intron 3 Exon 4 TGGATCCCTGTTCATTACT 
8 Intron 4 GATGTATGACAACAAGCTTTGCATC 
9 Intron 4 Exon 5 CTGATCTTCTGACACATTTTTGTTT 
10 Intron 5 AGCCAGGGGACCCAGAACCTGGG 
11 Intron 5 Exon 6 GAGAATTTCTCTAATCATCCGGCTG 
12 Intron 6 
13 Intron 6 
14 Intron 7 
15 Intron 7 
16 Intron 8 
17 Intron 8 
18 Intron 9 
19 Intron 9 
20 Intron 10 
ACATGTTAATGCATTTCGCACA 
Exon 7 AGTTCCTTGTCGGGCTTACCTTTGG 
AGGGCAGGGAGGCCATGTTGCTCCA 
Exon 8 CAACAAAGCCATGGGAAC 
AAGGAAGAGACTTGGAAGTCATGAC 
Exon 9 AGCTCACTCTGGGGCCTCAGGTGTC 
GATGACAAGGACTCCACAGCTG 
Exon 10 GATTGCTTCTGTGCCATGGTCTTTG 
TTCAAGAAAAGGAGAAGTT 
21 Intron 10 Exon 11 GATGAACTGAGGTACTTGTTATTCC 
22 3’-Untranslated, exon 11 GAGGAAAAGGTTGTGCTGGACTCCT 
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luminescence reagents (Amersham Corp., Arlington Heights, IL) were 
used to detect antigen-antibody complexes. 
Results 
Subjects 
The geographical, clinical, and genetic characteristics of 
the subjects studied are summarized in Table 1; these indi- 
viduals comprise about 45% of all subjects reported to date 
with 17PHSD deficiency. The affected individuals are from 
17 families and represent diverse ethnic groups. In all in- 
stances, except 1, the diagnosis of 17PHSD deficiency was 
based on characteristic clinical features, namely 46,XY males 
with pseudohermaphroditism, measurable or male serum 
testosterone levels, and elevated androstenedione levels. In 
1 instance (17HSD-3-Indianapolis), an infant with ambigu- 
ous genitalia was misdiagnosed as having 5cu-reductase 2 
deficiency, and the correct diagnosis was only made after 
molecular genetic analysis. Interestingly, only a single mu- 
tant allele was identified in the 17PHSD-3 gene in this in- 
dividual; we assume that the other allele probably contains 
a mutation outside the coding sequence of the gene, as het- 
erozygous males with other mutations of the gene are phe- 
notypically and endocrinologically normal. Alternatively, 
the individual might be a heterozygous carrier of the mu- 
tation and have some unidentified cause of ambiguous gen- 
italia. Of the subjects in Table 1, all have been raised as female 
except for 17HSD-3-Stony Brook, who is being raised as a 
male, and 17HSD-3-Gaza, some of whom are raised as males 
and some as females (11-14). 
In two subjects studied at the University of California-San 
Francisco, androstenedione and testosterone were measured 
in spermatic venous blood obtained by cannulation at the 
time of orchidectomy, and the levels were compared with 
normal spermatic vein measurements from the same labo- 
ratory (Table 2). Androstenedione levels in spermatic venous 
blood were elevated 15- to 20-fold, and testosterone levels 
were decreased 15- to 70-fold. The testosterone to andro- 
stenedione levels in these two subjects were 0.09 and 0.03, in 
contrast to normal ratios of 24-32. 
Mutations 
The mutations in this cohort are summarized in Table 1 
and Fig. 1. Fourteen different mutations have been identified 
325+4, 
S65L<6°Q\A~T (326~l,G+C 
in 12 homozygotes, 4 compound heterozygotes, and 1 pre- 
sumed compound heterozygote. These mutations occur in or 
affect the splicing of 7 exons and consist of 1 small deletion, 
3 splice site mutations, and 10 missense mutations that cause 
single amino acid substitutions in the protein. Three of these 
mutations were identified in more than 1 family. The R8OQ 
mutation, originally identified in homozygous form in 
17HSD-3-Gaza and in heterozygous form in 17HSD-3-Sao 
Paula 1 (4), was found in homozygous form in 17HSD-3-Sao 
Paula 3. Likewise, the 655-l,G+A splice acceptor site mu- 
tation previously described in 17HSD-3-Syria (4) is present 
in homozygous form in 17HSD-New York, and the 
325+4,A+T splice acceptor site mutation was present in 
homozygous form in 3 families and in heterozygous form in 
2 others (Table 1). 
Expression analysis of missense mutations 
To confirm that the coding sequence mutations are dele- 
terious, five of the missense mutations that cause single 
amino acid substitutions (S65L, V205E, F2081, E215D, and 
P282L) were introduced into expressible cDNA vectors by 
site-directed mutagenesis, and the enzyme activity was as- 
sessed after transfection into cultured cells by measuring the 
conversion of radioactive androstenedione to testosterone 
(Fig. 2A). The fact that the mutant cDNAs were expressed in 
the transfected cells was shown by immunoblotting using an 
antibody directed to a specific epitope of 17PHSD-3 (Fig. 2B). 
In each of the mutations studied, the substitution mutation 
appeared to inactivate enzyme activity almost completely 
(Fig. 2A). Thus, of the nine substitution mutations analyzed 
by this technique to date (4), only the R80Q mutation appears 
to possess residual enzyme activity when studied in this 
manner, namely approximately 20% of the normal activity. 
DISCUSSION 
17/3HSD-3 deficiency is a rare autosomal recessive cause of 
male pseudohermaphroditism. The typical subject with this 
disorder is a 46,XY male who is born with a female external 
phenotype (but with testes located in the inguinal canals or 
labia majora) and who undergoes considerable virilization at 
the time of expected puberty associated with elevated levels 
of blood androstenedione and either low or normal male 
3 - Splice Junction 
10 - Substitution 
1 - Small Deletion 
/ \ 
Q176P A777-763 
FIG. 1. Mutations in steroid 17PHSD-3 gene in subjects with 17/3HSD deficiency. Exons are numbered with Roman numerals and are 
indicated by open squares connected by introns (clashed lines). Neither introns nor exons are drawn to scale. Substitution mutations in 
the different exons are indicated above the diagram by the single letter code. The normal amino acid appears first, followed by the residue 
number in the proenzyme and the mutant amino acid. A, A small deletion in exon 10 of the gene. The locations of splice junction mutations 
are indicated by the closest nucleotide in the exon t the number of nucleotides to the mutation. For example, the mutation 325+4,A+T 
is an A to T transversion mutation located four nucleotides downstream of the exon S/intron 3 boundary. Nucleotide number 325 is the 
last base of exon 3 in the sequenced cDNA (4). 
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FIG. 2. Expression analysis of normal and mutant 17PHSD-3 isoen- 
zymes. cDNAs encoding the normal type 3 isoenzyme or a protein 
harboring the indicated amino acid substitution mutation were trans- 
fected into cultured human embryonic kidney 293 cells on day 0. On 
day 2, the medium was supplemented with 2 pmol/L [i4Clandro- 
stenedione (53 mCi/mmol), and the incubation was continued for the 
indicated time period. Thereafter, the medium was harvested, and the 
conversion of androstenedione to testosterone was monitored by thin 
layer chromatography (A). In B, 5-pg aliquots of total cell lysate on 
day 3 of the experiment were analyzed by immrmoblotting using an 
antipeptide antibody directed against the 17PHSD-3 isoenzyme. The 
protein migrates with an apparent mol wt of 30,000 and is present in 
all transfected cells at approximately the same levels. 
levels of testosterone (7-9). [Occasional individuals have am- 
biguous genitalia at birth (241, and two late-onset variants of 
uncertain pathophysiology have been described, one mani- 
fest by gynecomastia in boys (25,261 and the other as poly- 
cystic disease in women (27j.l 
It has been recognized for approximately 25 yr that this 
disorder is the result of a defect in the final step in testos- 
terone synthesis in the testes, namely the conversion of an- 
drostenedione to testosterone (5,6). We have shown that the 
molecular basis of this disorder is any of several mutations 
in the 17/3HSD-3 gene, a gene that appears to be expressed 
predominately or exclusively in testes (41. In the present 
report we describe 9 additional mutations in this gene to 
make a total of 14 different mutations in 17 subjects/families. 
Twelve are present in homozygous form, 4 are compound 
heterozygotes, and 1 is a presumed compound heterozygote. 
These mutations consist of a 7-nucleotide deletion that causes 
a frame shift, 3 splice site abnormalities, and 10 missense 
mutations that cause amino acid substitutions. Three of these 
mutations (R8OQ, 655-1, G+ A, and 325 + 4,A-+ T) have been 
identified in more than 1 family; we do not know at present 
whether this recurrence is due to a founder effect or to re- 
current new mutations. 
Two characteristic features of the disorder are particularly 
puzzling: 1) the defect in virilization and the deficiency in 
testosterone synthesis are usually more complete during em- 
bryogenesis than in later life, implying that an alternate route 
for testosterone synthesis must be activated at the time of 
expected puberty; and 2) the external genitalia at birth are 
usually female in character, but the Wolffian duct structures 
(epididymides, vasa deferentia, and seminal vesicles) virilize 
normally, indicating that androgen must act by an alternate 
mechanism in these tissues in utero. 
The findings in the present study provide insight into the 
source of circulating testosterone after the time of expected 
puberty in this disorder. Two theories have been proposed to 
explain this phenomenon. First, Akesode and his colleagues 
(10) concluded on the basis of studies of the metabolism of 
radioactive precursors in a single affected subject (17HSD-3- 
Syria) that testosterone is formed from circulating andro- 
stenedione by extraglandular conversion. Second, on the basis 
of studies of the hormone concentrations in testicular venous 
blood from several related subjects from the Gaza strip (VHSD- 
3-GazaJ E&stein et aI. 01) demonstrated that considerable 
amounts of testosterone can be secreted by the testes of affected 
members of that kindred. Using site-directed mutagenesis and 
transient transfection assays, we demonstrated that eight of the 
nine missense mutations inactivate enzyme activity almost 
completely. Furthermore, in two of the individuals with inac- 
tive n&sense mutations, assessment of testosterone and an- 
drostenedione levels in testicular venous blood indicated that 
these individuals secrete only 5% as much testosterone from the 
testes as normal controls. This finding is in keeping with the fact 
that the expressed enzyme from the subject described by 
Akesode et al. (10) (VI-ISD+Syria) was also inactive when 
transiently expressed in reporter cells (4). As the other muta- 
tions characterized to date, the frame-shift mutation and the 
splice acceptor site abnormalities, are predicted to preclude the 
formation of functional protein, we conclude that the common 
mechanism for testosterone synthesis (and for the resulting 
virilization) after the time of expected puberty in this disorder 
is by extraglandular formation. It is of interest in this regard that 
in the one exception to this generalization (subjects from the 
Gaza family who carry the RSOQ mutation), not only was tes- 
tosterone secreted by the testes (10, but in addition, the ex- 
pression of the reconstructed DNA containing this mutation 
caused the formation of an enzyme with about 15-20% of nor- 
mal enzyme activity at high substrate concentrations (4). 
Whether the enzyme responsible for extraglandular con- 
version of androstenedione to testosterone is isoenzyme 1 or 
2 or some other 17PHSD enzyme is, at present, unclear, nor 
is it understood why this process seems to be more efficient 
in later life than during embryogenesis. The enhancement of 
testosterone synthesis at the time of expected puberty may 
be the consequence of the increased output of androstenedi- 
one by the testes after the pubertal surge of LH secretion and, 
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hence, the availability of more substrate for testosterone syn- 
thesis in extraglandular sites by other isoenzymes. 
The present studies also leave unexplained the virilization 
of the Wolffian ducts in these subjects during fetal life. At the 
simplistic level, virilization in the absence of circulating tes- 
tosterone could be due to the presence in the tissue of an 
embryonic receptor mechanism that lacks the specificity of 
the mature androgen receptor or to the presence in the tissue 
of an alternate mechanism for the conversion of circulating 
androstenedione. So far as can be ascertained, the embryonic 
Wolffian duct androgen receptor is identical to the receptor 
in other tissues (28), and we, therefore, conclude that this 
tissue must contain an alternate pathway for testosterone 
formation, possibly the same 17PHSD responsible for ex- 
traglandular testosterone formation in later life. The mech- 
anism by which the Wolffian ducts virilize in this disorder 
is now under scrutiny. 
Extraglandular testosterone formation may also be respon- 
sible for one other unexpected finding in the present study. 
Namely, 1 of the 16 homozygotes/compound heterozygotes in 
the present study (VHSD-3-Stony Brook) had clear-cut ambig- 
uous genitalia at the time of birth, implying considerable tes- 
tosterone formation during embryogenesis. It was, therefore, 
unexpected that when the reconstructed DNA containing this 
mutation (F2081) was expressed in reporter cells, the mutant 
17PHSD was totally inactive. It is possible that there is consid- 
erable genetic variability among individuals in the capacity for 
extraglandular testosterone formation. 
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